Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417306 | 0.86 | HTT (0.73) | HTTFGFR1POLBROCK1ALDH1A1 | |
| SCHEMBL23840275 | 0.85 | FGFR1 (0.58) | HTTFGFR1POLBROCK1ALDH1A1 | |
| SCHEMBL10094534 | 0.81 | FGFR1 (0.48) | HTTFGFR1POLB | |
| SCHEMBL23266636 | 0.81 | HTT (0.60) | HTTFGFR1POLBROCK1ALDH1A1 | |
| SCHEMBL14500118 | 0.80 | HCAR1 (0.50) | HTTFGFR1HCAR1ALDH1A1 | |
| SCHEMBL20603955 | 0.80 | FGFR1 (0.51) | HTTFGFR1POLBROCK1ALDH1A1 | |
| SCHEMBL23840256 | 0.79 | HTT (0.58) | HTTFGFR1POLBROCK1ALDH1A1 | |
| SCHEMBL56852 | 0.79 | FGFR1 (0.61) | HTTFGFR1POLBALDH1A1 | |
| SCHEMBL24179153 | 0.78 | FGFR1 (0.51) | HTTFGFR1HCAR1POLBALDH1A1 | |
| SCHEMBL8869907 | 0.78 | HTT (0.56) | HTTFGFR1POLBROCK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097618-B1 | POST-TREATMENT FOR COPPER ON PRINTED CIRCUIT BOARDS | FRYS METALS INC DBA ALPHA METALS INC (US) | 2003-03-26 | — | — | EP | claimed |
| CN-108794536-B | Organic electroluminescent material and device | 环球展览公司 | 2023-06-20 | — | — | CN | disclosed |
| US-10910570-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-10910570-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180315935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2018-11-01 | — | — | US | disclosed |
| US-9865952-B2 | Plug contact with organic coating and printed circuit board arrangement | CONTINENTAL AUTOMOTIVE GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-20170179628-A1 | PLUG CONTACT WITH ORGANIC COATING AND PRINTED CIRCUIT BOARD ARRANGEMENT | CONTINENTAL AUTOMOTIVE GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-0251760-B1 | Rubber composition | BRIDGESTONE CORP (JP) | 1994-01-26 | — | — | EP | disclosed |
| US-5140055-A | Improved high speed grip performance | BRIDGESTONE CORPORATION (JP) | 1992-08-18 | — | — | US | disclosed |
| EP-0251760-A2 | Rubber composition | Bridgestone Corporation (JP) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180315935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ORC3, ICMT, OR10J3 | HTT 3793/4885FGFR1 3539/4885HCAR1 4408/4885 |
| US-10910570-B2 | Organic electroluminescent materials and devices | ORC3, ICMT, OR10J3 | HTT 3793/4885FGFR1 3539/4885HCAR1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.